Fibrates in the metabolic syndrome and in diabetes.
There is increasing evidence that fibrates can reduce coronary artery disease. This finding seems to be particularly the case inpatients with the metabolic syndrome or with diabetes. Their beneficial effects can be explained partly by their effects on lipoproteins,but these effects may also result from some of their nonlipid pleotropic effects. Clinical trials are still needed to determine the potential role played by such pleotropic actions.
Steiner
George
G
Division of Endocrinology and Metabolism, Toronto General Hospital, 200 Elizabeth Street, Toronto, Ontario, Canada M5G 2C4. george.steiner@uhn.on.ca
D018680:Cholinergic Antagonists / Q000627:therapeutic use*; D003924:Diabetes Mellitus, Type 2 / Q000188:drug therapy*; D006801:Humans; D024821:Metabolic Syndrome / Q000188:drug therapy*
D018680:Cholinergic Antagonists